Articles tagged with Interleukins
Researchers discovered biomarkers indicating overactivity and dysfunction in the immune system, which can lead to chronic critical illness. Identifying these markers could allow doctors to intervene earlier, leading to shorter ICU stays and improved patient outcomes.
Researchers found that running high-intensity interval training (HIIT) triggers a more inflammatory immune response than cycling HIIT. Cycling produced a similar anti-inflammatory effect compared to running, suggesting it could be used in exercise programs to achieve beneficial effects without tissue damage.
Interleukin 6 is investigated as a treatment target for depression in this randomized clinical trial. The study highlights the therapeutic potential of IL-6 or IL-6 receptor inhibition and proposes suitable patient selection methods.
A first-in-human trial demonstrates the potential of implantable cytokine factories for treating ovarian cancer, showing a favorable safety profile and encouraging disease stabilization in patients. The therapy successfully activated key immune cells without expanding regulatory T cells, revealing a promising mechanism of action.
Researchers found that patients with major depressive disorder share immune abnormalities with inflammatory skin diseases, including atopic dermatitis. The study suggests targeting the Th2 pathway and interleukin-4 receptor alpha as potential therapeutic strategies for psychiatric illness.
Researchers found that psilocybin reduced novelty-seeking in control mice, but heightened it in anorexia model mice. Inflammation levels were also altered, contradicting expectations based on human studies. The study's findings have implications for understanding anorexia nervosa and the potential therapeutic effects of psychedelics.
Researchers at Penn State College of Medicine discovered a new function of antibody-making B cells in response to flu infection. These cells produce a key signaling molecule called interleukin-1 beta, which is necessary for developing a robust immune response and forming optimal germinal centers.
The interleukin family is involved in the development of acute kidney injury through inflammatory and fibrotic mechanisms. Protective ILs like IL-2, IL-10, and IL-37 mitigate injury, while pro-inflammatory ILs such as IL-1α and IL-18 exacerbate damage.
A new cytokine delivery platform reprograms the tumor microenvironment to enhance CAR-T cell function in preclinical brain cancer models. The strategy leads to a broader immune response that inhibits tumor growth and extends host survival, even in mice with only a fraction of cells expressing the CAR-targeted antigen.
Researchers found that cortisol levels were lower in survivors, while heart rate and blood pressure responses were altered. Interleukin 1B was significantly higher, suggesting potential long-term health problems despite healthy symptoms.
A new study published in The Journal of Immunology found that a high-salt diet induces depression-like symptoms in mice by driving the production of IL-17A. Researchers identified gamma-delta T cells as an important source of this protein, which is also linked to depression in human clinical studies.
A recent study explores the connection between chronic inflammation and arrhythmia development, identifying potential therapeutic targets for preventing and treating AF. The research team discovered that interleukin-1 beta (IL-1β) triggers atrial fibrillation by activating its receptors on macrophages.
The Micro Immune Response On chip (MIRO) replicates tumours and their environment, allowing researchers to study the efficacy of immunotherapy treatments. This technology has been tested with breast cancer samples and shows promise in understanding how the immune system interacts with tumours.
A new study using a novel mouse strain expressing Halo-tagged SOCS1 reveals that the inhibitor needs to exceed a threshold level to suppress GM-CSF and IFN-gamma signaling. The findings emphasize SOCS1's crucial function in modulating cytokine signaling.
Rice bioengineers create a mathematical model that challenges long-held assumptions about IL-12's behavior in the body, suggesting repeated doses cause immune cells to hoard IL-12 before it reaches the bloodstream. The findings have significant implications for IL-12 therapy design and may lead to more effective dosing regimens.
A new study suggests that immunotherapy may be an effective treatment strategy for heart failure by blocking scar tissue formation and improving heart function. Researchers identified a type of fibroblast cell responsible for scar tissue and used a monoclonal antibody to reduce its formation, showing promising results in mouse models.
Researchers from the Hubrecht Institute found that tuft cells can proliferate and generate new epithelial cell types, restoring damaged gut tissue. This discovery may have important implications for regenerative medicine.
Researchers have discovered that administering regulatory T cells (Tregs) can enhance tissue healing, promoting bone volume, muscle growth, and skin wound closure. The key role of interleukin-10 (IL-10) in supporting tissue repair has also been identified.
CNIO researchers have discovered a 'switch' for the desire to engage in physical activity, revealing a muscle-brain pathway that controls eagerness to train more when we exercise. Two proteins, p38α and p38γ, get activated in the muscle during exercise, influencing interest in physical activity.
A study identified a protein called IL-22BP that affects the composition of gut microbiota and the body's response to bacterial infection. The absence of this protein results in stronger defenses against intestinal infections, including increased production of short-chain fatty acids that promote an anti-inflammatory environment.
Researchers discovered that deactivating IL-11 increases healthy lifespan by 20-25% in mice, with reduced cancer deaths, fibrosis, chronic inflammation, and improved muscle strength. The findings raise the possibility of using anti-IL-11 treatments to study aging in humans.
Researchers found significantly higher levels of IL-18 expression in osteoarthritis patients and cells compared to healthy controls. IL-17 promoted IL-18 production through the MEK/ERK/miR-4492 axis, indicating potential therapeutic targets for OA treatment.
A new study found that the gut microbiota plays a significant role in prostate inflammation in aging men, particularly those with metabolic syndrome. The researchers discovered a strong relationship between IL-6 and IL-18 expression and lipid parameters in the prostate tissue of men with BPH + MetS.
A recent study found a compelling link between vitamin B12 deficiency and chronic inflammation, which can lead to various health problems. The research revealed an inverse relationship between vitamin B12 levels and inflammatory markers in humans and mice, suggesting that higher vitamin B12 levels may lower inflammatory markers.
Researchers found that expression of CiDRE in alveolar macrophages makes patients more susceptible to SARS-CoV-2 invasion and promotes cytokine storm. The genetic quirk is associated with severe COVID-19 symptoms, suggesting potential treatments targeting IL-10R and CiDRE.
Researchers found that IL-6 signaling in allergen-specific T cells was needed to suppress commitment to the harmful Th2 lineage. SOCS3 upregulation by IL-6 inhibits JAK/STAT internal signaling pathway, preventing Th2 cell priming.
Scientists from Trinity College Dublin discovered that Interleukin-37 activates the immune system, contrary to earlier theories. This finding has significant implications for understanding and treating autoimmune disorders and inflammation.
Researchers at Cedars-Sinai found that estrogen can prevent symptoms of delirium in mice with urinary tract infections, reducing IL-6 levels in the blood and protecting neurons. The study suggests estrogen may be a tool to mitigate delirium, particularly in older women with UTIs.
A study reveals that interleukin 34 (IL-34) modulates the balance between two myeloid-derived suppressor cell populations, leading to immunosuppression and chemoresistance in triple-negative breast cancer. Neutralizing IL-34 with a drug reduces tumor growth and susceptibility to chemotherapy.
A global team of researchers, including Professor Stuart Cook, has won £30M to develop an injectable cure for genetic heart conditions. The team aims to pioneer gene therapy technologies to silence or edit faulty genes causing deadly conditions.
Researchers at Hokkaido University have discovered a molecular pathway by which stress affects lupus, revealing a potential target for treatment. The study found that sleep deprivation caused the activation of microglial cells in the brain, leading to increased levels of IL12 and IL23, a diagnostic marker for neuropsychiatric SLE.
A detailed understanding of interleukin 2's role in the immune system has been gained through a new mouse model, enabling scientists to identify potential new uses as an immune-modulating biologic drug. This breakthrough may lead to optimized autoimmune and cancer treatment while avoiding unwanted side effects.
Scientists at CNIC discovered a complex network between liver tissue connections that allows the liver to regulate body temperature. The secretion of IL-12 by liver-infiltrating macrophages blocks FGF21 production, reducing heat generation by brown fat in mice.
Researchers at Texas Biomedical Research Institute have found that adding an antibody to the widely-used TB vaccine significantly improves its long-term effectiveness. The combination of the vaccine and an IL-10 blocker allows for better control of TB infection in mice, with improved lung health and increased memory immune cells.
Researchers created implantable beads that produce high concentrations of interleukin-2, a natural compound activating white blood cells to fight cancer. The treatment eradicated ovarian and colorectal cancer in mice within six days, paving the way for human clinical trials later this year.
Researchers developed a new SERS-based multiplexing technique to detect kidney injury biomarkers SLPI and IL-18, achieving high sensitivity and reliability. The approach shows promise for objectively assessing donor kidney quality, potentially reducing discard rates and recipient complications in clinical practice.
Researchers discovered that infections improve the production and function of naïve T cells, the body's first line of defense against disease. This mechanism involves interleukin 7 and MHC molecules, which signal naïve T cells to stay alive and receive optimal metabolic signals.
Researchers at Karolinska Institutet discovered that interleukin-26 plays a critical role in bacterial pneumonia by directly killing bacteria and modulating the immune system. This finding positions IL-26 as a new potential target for biological treatment of pneumonia, an increasing global health threat.
A new study suggests that drinking 100% orange juice significantly reduces interleukin 6, a well-established marker of inflammation, in both healthy and high-risk adults. However, the results did not quite reach statistical significance for two additional inflammatory and oxidative stress markers.
A case series examines the association of interleukin 7 (IL-7) immunotherapy with restored host protective immunity in patients with severe COVID-19 and immunosuppression. The study found that IL-7 treatment led to increased lymphocyte counts, suggesting a potential therapeutic benefit.
A portfolio start-up company of the AIM-HI Accelerator Fund, ILCT is developing engineered therapeutic interleukins for cancer treatment. The grant will support collaboration with Virginia Commonwealth University towards development of its commercialization efforts.
Chaperones, molecular protein machines, ensure that proteins are built correctly. In the study, researchers found that chaperones retain one part of interleukin 23-alpha until it is incorporated into the complete complex, controlling its secretion and biosynthesis.
Researchers found that two specific biomarkers were elevated in athletes who experienced concussions, indicating potential for longer recovery times. The study suggests these biomarkers could aid in predicting which athletes are more likely to need extended recovery periods after concussion.
Researchers have discovered how glutamine controls gene programs in cells, revealing a new mechanism of differentiation and gene regulation. This finding has significant implications for understanding developmental biology, the immune response, and cancer dysregulation.
Research suggests a connection between psoriasis and psychiatric illnesses, with inflammation being a key underlying factor. Psoriasis patients are at higher risk of anxiety, depression, and suicidal thoughts due to the debilitating nature of their condition.
A study of over 1,800 patients found that tildrakizumab significantly improved skin conditions in those with moderate-to-severe psoriasis. The treatment demonstrated a 75% improvement in PASI scores at 12 weeks, with fewer than 10% of placebo recipients showing similar results.
A Johns Hopkins Medicine study found that air pollution directly causes inflammation in the nasal and sinus tissues of mice. The researchers exposed mice to polluted air for 16 weeks, showing increased white blood cells and biomarkers of inflammation.
Researchers found that SHARPIN protein inhibits caspase 1 activation, which is linked to sepsis. Treatment with a caspase 1 inhibitor reversed effects in mice and showed promise in human patients.
Researchers discovered a new molecule, 101.10, that effectively prevents inflammation-induced uterine contractions and premature delivery without harming the fetus or mother. The study is a significant step towards preventing prematurity, the world's leading cause of infant death.
A new study by UC San Francisco researchers found that two signaling molecules secreted by immune cells trigger the conversion of white fat cells to beige fat cells, leading to weight loss. The discovery provides a potential new strategy for weight loss focused on the immune system rather than the brain.
Researchers at Medical College of Georgia are investigating the potential of brilliant blue G to treat traumatic brain injuries. The dye may temporarily block an immune response that leads to swelling, which can cause damage to brain tissue.
A study published in The Journal of Immunology found that Interleukin 21 (IL-21) contributes to fatal inflammatory disease, particularly when another cytokine is deficient. Removing IL-21 can greatly subdue the inflammatory response and may help people with chronic inflammation due to defective T cell regulation.
Researchers from Monash University identified interleukin 37 as a key therapy for many inflammatory diseases, including those affecting premature babies. The protein blocks inflammation throughout the body and has been activated by various biological triggers.
A study by University of Bonn researchers has found a link between the influenza virus and fever, revealing that the immune system's RIG-I protein plays a key role in triggering high temperatures. This discovery could lead to new therapeutic strategies for treating severe viral infections.
A study led by Professor Derry Roopenian found that a blocked protein called Interleukin 21 prevents systemic lupus erythematosus (SLE) in mice. The researchers also demonstrated the importance of IL21 signaling in SLE progression, suggesting that interrupting this process could be an effective therapeutic option for human SLE patients.
A study led by UAB researchers found that blocking interleukin 17 (IL-17) slows disease-causing B cell actions in autoimmune disorders like rheumatoid arthritis and lupus. This discovery highlights IL-17's role in shaping B cells' ability to create more antibodies.
New research reveals that the immune system's 'thermostat' operates in harmony, with pro-inflammatory and anti-inflammatory compounds working together to regulate inflammation. Interleukin 10 production is triggered by Interferon-γ and an antigen-presenting cell, highlighting a dynamic and coordinated response.
The study reveals that retroviral protein p12 stimulates the growth and proliferation of immune cells known as T lymphocytes by producing interleukin 2 (IL-2). This finding supports the view that HTLV-1 virus replicates mainly by causing infected cells to divide and proliferate.
USC researchers have identified a protein fragment, PEP, that can increase the effectiveness of chemotherapy drugs against tumors. By making tumor blood vessels more permeable, PEP allows for better drug uptake and increased chemotherapy efficacy.
Researchers at Vanderbilt University Medical Center have identified a new protein called Interleukin 24 (IL-24) that is expressed in colon cancer cells and promotes cell growth or prevents cell death. The discovery could lead to the development of molecules to interrupt an autocrine loop, potentially fueling tumor growth.